Clinical features and course of brain metastases in triple-negative breast cancer: Comparison with human epidermal growth factor receptor 2-positive and other type at single institution in Korea

Breast Cancer Research and Treatment

Volumn 128, Issue 1, 2011, Pages 171-177

  Jang, Geundoo ^a   Lee, Sung Sook ^a   Ahn, Jin Hee ^a   Jung, Kyung Hae ^a   Lee, Hyunjoo ^a   Gong, Gyungyub ^a   Kim, Hak Hee ^a   Ahn, Seung Do ^a   Son, Byung Ho ^a   Ahn, Sei Hyun ^a   Kim, Sung Bae ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Brain metastases; Breast cancer; Human epidermal growth factor receptor 2; Triple negative

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL FEATURE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; GAMMA KNIFE RADIOSURGERY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; SOUTH KOREA; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; KOREA; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES;

EID: 79959198173     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1526-y     Document Type: Article

References (32)

1. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 10963602 10.1038/35021093 1:CAS:528: DC%2BD3cXmt1CnsLw%3D
2. TO Nielsen FD Hsu K Jensen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 15328174 10.1158/1078-0432.CCR-04-0220 1:CAS:528:DC%2BD2cXmvFSlt7k%3D (Pubitemid 39100473)
3. JS Reis-Filho AN Tutt 2008 Triple negative tumours: a critical review Histopathology 51 108 118 (Pubitemid 350265179)
4. WJ Irvin Jr LA Carey 2008 What is triple-negative breast cancer? Eur J Cancer 44 2799 2805 19008097 10.1016/j.ejca.2008.09.034 1:CAS:528: DC%2BD1cXhsVKltr%2FE
5. T Sorlie CM Perou R Tibshirani, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 10869 10874 11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D (Pubitemid 32878711)
6. WD Foulkers JS Brunet IM Stefansson, et al. 2004 The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid- microvascular-proliferation+) phenotype of BRCA1-related breast cancer Cancer Res 64 830 835 10.1158/0008-5472.CAN-03-2970 (Pubitemid 38176880)
7. BG Haffty Q Yang M Reiss, et al. 2006 Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer J Clin Oncol 24 5652 5657 17116942 10.1200/JCO.2006.06.5664 (Pubitemid 46631305)
8. A Di Sterano Y Yong Yap GN Hortobagyi, et al. 1979 The natural history of breast cancer patients with brain metastases Cancer 44 1913 1918 10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO;2-D (Pubitemid 10141974)
9. T Fokstuen N Wilking LE Rutqvist, et al. 2000 Radiation therapy in the management of brain metastases from breast cancer Breast Cancer Res Treat 62 211 216 11072785 10.1023/A:1006486423827 1:STN:280:DC%2BD3M3osFSnug%3D%3D
10. SS Lee JH Ahn MK Kim, et al. 2008 Brain metastases in breast cancer: prognostic factors and management Breast Cancer Res Treat 111 523 530 17990100 10.1007/s10549-007-9806-2
11. NU Lin JR Bellon EP Winer 2004 CNS metastases in breast cancer J Clin Oncol 22 3608 3617 15337811 10.1200/JCO.2004.01.175 (Pubitemid 41103668)
12. M Ryberg D Nielsen K Osterlind, et al. 2005 Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy Breast Cancer Res Treat 91 217 225 15952055 10.1007/s10549-005-0323-x (Pubitemid 40896568)
13. DG Kirsch CJ Ledezma CS Mathews, et al. 2005 Survival after brain metastases from breast cancer in the trastuzumab era J Clin Oncol 23 2114 2116 15774813 10.1200/JCO.2005.05.249 (Pubitemid 46211402)
14. JC Bendell SM Domchek HJ Burstein, et al. 2003 Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast cancer Cancer 97 2972 2977 12784331 10.1002/cncr.11436 (Pubitemid 36676250)
15. DN Church R Modgil S Guglani, et al. 2008 Extended survival in women with brain metastases from HER2 overexpressing breast cancer Am J Clin Oncol 31 250 254 18525303 10.1097/COC.0b013e31815a43c4 1:CAS:528:DC%2BD1cXntFWgu7k%3D
16. IH Park J Ro KS Lee, et al. 2009 Trastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancer Ann Oncol 20 56 62 18664558 10.1093/annonc/mdn539 1:STN:280:DC%2BD1M%2Fns1yltA%3D%3D
17. A Reiner G Reiner J Spona, et al. 1998 Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. A comparison of immunocytochemical and biochemical analysis Cancer 15 1149 1154
18. JS Barnholtz-Sloan AE Sloan FG Davis, et al. 2004 Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System J Clin Oncol 22 2865 2872 15254054 10.1200/JCO.2004.12.149 (Pubitemid 41079905)
19. F Heitz P Harter HJ Lueck, et al. 2009 Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases Eur J Cancer 45 2792 2798 19643597 10.1016/j.ejca.2009.06.027 1:CAS:528:DC%2BD1MXhtlSqsL3M
20. YL Tham K Sexton R Kramer, et al. 2006 Primary breast cancer phenotypes associated with propensity for central nervous system metastases Cancer 107 696 704 16826579 10.1002/cncr.22041 (Pubitemid 44232661)
21. BH Nam SY Kim HS Han, et al. 2008 Breast cancer subtypes and survival in patients with brain metastases Breast Cancer Res 10 1 R20 10.1186/bcr1870 18307763 10.1186/bcr1870
22. A Niwinska M Murawska K Pogoda 2010 Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT) Ann Oncol 21 942 948 19840953 10.1093/annonc/mdp407 1:STN:280:DC%2BC3c3ptFyntA%3D%3D
23. MJ Kim JY Ro SH Ahn, et al. 2006 Clinicopathologic significance of basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes Hum Pathol 37 1217 1226 16938528 10.1016/j.humpath.2006.04.015 1:CAS:528:DC%2BD28XovVWrt7k%3D (Pubitemid 44286991)
24. ME Hammond DF Hayes M Dowsett, et al. 2010 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 28 2784 2795 20404251 10.1200/JCO.2009.25.6529
25. JM Harvey GM Clark CK Osborne DC Allred 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer J Clin Oncol 17 1474 1481 10334533 1:STN:280:DyaK1M3msFOjsA%3D%3D (Pubitemid 29220854)
26. AF Eichler I Kuter P Ryan, et al. 2008 Survival in patients with brain metastases from breast cancer: the importance of HER-2 status Cancer 112 459 469 10.1002/cncr.23468
27. T Pienkowski CC Zielinski 2010 Trastuzumab treatment in patients with breast cancer and metastatic CNS disease Ann Oncol 21 917 924 19717536 10.1093/annonc/mdp353 1:STN:280:DC%2BC3c3ptFOmtA%3D%3D
28. AJ Clayton S Danson S Jolly, et al. 2004 Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer Br J Cancer 91 639 643 15266327 1:CAS:528:DC%2BD2cXmsVCgs7k%3D (Pubitemid 39141617)
29. KD Miller T Weathers LG Haney, et al. 2003 Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on survival Ann Oncol 14 1072 1077 12853349 10.1093/annonc/mdg300 1:STN:280:DC%2BD3szitlCrtg%3D%3D (Pubitemid 36950171)
30. ME Melisko M Glantz HS Rugo 2009 New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer Nat Clin Pract Oncol 6 25 33 18936791 10.1038/ncponc1243 1:CAS:528:DC%2BD1cXhsFWkurzJ
31. NU Lin EP Winer 2007 Brain metastases: the HER2 paradigm Clin Cancer Res 13 1648 1655 17363517 10.1158/1078-0432.CCR-06-2478 1:CAS:528: DC%2BD2sXivV2gtro%3D (Pubitemid 46952930)
32. CE Geyer J Forster D Lindquist, et al. 2006 Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 28 2733 2743 10.1056/NEJMoa064320 (Pubitemid 46021510)